Anesthetic

Surmodics Announces SWING Trial 12-Month Data to be Presented at VEITHsymposium on November 16

Retrieved on: 
Friday, November 11, 2022
Medical Devices, Health, Surgery, Clinical Trials, General Health, Pharmaceutical, Aortoiliac occlusive disease, Sale, Company, Annual report, NASDAQ, Disease, Auckland City Hospital, Technology, Cell, DCB, SEC, Safety, Investor, 3rd Floor, Forward-looking statement, MS, Restenosis, Master of Medicine, FRANZCR, AMP, Growth, Amputation, PHD, ONZM, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery, FRACS, Anesthetic, MBBS

The session will be held on Wednesday, November 16, at the 49th Annual Symposium on Vascular and Endovascular Issues (VEITHsymposium) in New York City.

Key Points: 
  • The session will be held on Wednesday, November 16, at the 49th Annual Symposium on Vascular and Endovascular Issues (VEITHsymposium) in New York City.
  • Professor Andrew Holden, MBChB, FRANZCR, EBIR, ONZM, Director of Northern Region Interventional Radiology Service at Auckland City Hospital in Auckland, New Zealand, is also a co-lead investigator for the SWING Trial.
  • Professor Varcoe recently presented SWING Trial 6-month data on October 11 as part of the Amputation Prevention Symposium (AMP) in Lugano, Switzerland.
  • Surmodics is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays.

Cali Biosciences Announces Publications of Phase IIa Results of Long-Acting Ropivacaine (CPL-01)

Retrieved on: 
Thursday, October 27, 2022
Association, Ropivacaine, LLC, Toxicity, Anesthesia, PI, Manuscript, National Association Medical Staff Services, Pharmacokinetics, Annual general meeting, Innovation, Injection, Technology, FDA, Safety, AAPS, Patient, Bupivacaine, Research, Literature, Analgesic, Poster, Anesthetic, Pharmacy, Pain, American Association, Pharmaceutical industry, Medicine, Abdominoplasty

SAN DIEGO, Oct. 26, 2022 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinafter referred to as "Cali Biosciences"), a biopharmaceutical company focused on the research and development of innovative drugs, announced two major milestones for CPL-01, its long-acting ropivacaine for post-operative analgesia and opioid elimination/reduction:

Key Points: 
  • CPL-01 is an extended-release injectable version of Naropin (ropivacaine hydrochloride), developed by Cali Biosciences to treat post-operative surgical pain and reduce or eliminate the need for opioids.
  • PJ Chen, Chief Executive Officer of Cali Biosciences, commented, "CPL-01 is the core product of Cali Biosciences' product pipeline in our perioperative program, which also includes anesthetics, and long-acting anti-inflammatories.
  • Cali Biosciences US, LLC was established inSan Diego,USA, in 2016, and later Cali Biosciences built its global headquarter inShenzhenand a Clinical Development Center inShanghai, China.
  • Cali Biosciences' product pipeline includes modified formulations and new drugs in the fields of anesthesia, analgesia and anti-inflammatory.

Anesthesia Monitoring Devices Market to Exceed US$ 3.4 Billion by 2027 Amid Rising Prevalence of Degenerative and Chronic Illnesses

Retrieved on: 
Wednesday, October 26, 2022
Physician, Method, Hospital, Prevalence, Growth, Degenerative disease, Anesthesia, Getinge, Confusion, CAGR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Inhalation, NEW, Food, Vomiting, Malignant hyperthermia, Awareness, Chills, Patient safety, Anesthetic, Sore throat, FDA, Data analysis, Solution, Video game, Medical device, Risk management

NEW YORK, Oct. 26, 2022 /PRNewswire/ -- The global anesthesia monitoring devices market is projected to grow from US$ 2.2 Billion in 2022 to US$ 3.4 Billion in 2027. As per the study, overall sales are slated to expand at an impressive CAGR of 9.1% over the forecast period (2022-2027).

Key Points: 
  • NEW YORK, Oct. 26, 2022 /PRNewswire/ --The global anesthesia monitoring devices market is projected to grow from US$ 2.2 Billion in 2022 to US$ 3.4 Billion in 2027.
  • Increasing number of surgical cases is likely to drive growth in the anesthesia monitoring devices market during the forecast period.
  • Rising technological advancements and developments in the field of anesthetic delivery technology are also expected to drive growth in the anesthesia monitoring devices market.
  • As a result of the rising need for continuous monitoring, the anesthesia monitoring devices market is set to expand.

Capital Hair Center in Istanbul Draws Attention in Turkiye's Rising Hair Transplant Sector With Its Cutting-edge Ozone Therapy

Retrieved on: 
Thursday, October 20, 2022
Other Travel, Health, Destinations, Travel, Health Technology, Consumer, Other Consumer, Other Health, Hair, Tourism, Anesthetic, Patient, Transplant, Survival rate, Medical tourism, Multimedia, Health, Health economics, Dentistry

View the full release here: https://www.businesswire.com/news/home/20221020005585/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221020005585/en/
    Capital Hair Center in Istanbul draws attention in Turkiye's rising hair transplant sector with its cutting-edge ozone therapy (Photo: Business Wire)
    Nowhere has this been more apparent than in the global hair-transplantation market, which is forecast to reach a total value of $30.13 billion per year by 2031.
  • Thousands of people from all over the world visit Turkiye for top-notch and competitively priced hair-transplant procedures, Dr. Ekrem Keskin of Istanbuls Capital Hair Center says.
  • Capital Hair Center offers patients cutting-edge ozone therapy, which boosts the survival rate of transplanted hair grafts and accelerates the recovery process.
  • "After performing a scalp analysis, the centers experienced staff can determine how many hair grafts are needed, and where."

Piramal Pharma Limited lists on BSE and NSE

Retrieved on: 
Wednesday, October 19, 2022
Scrip, Allergan, National Stock Exchange, Growth, Piramal Group, The Carlyle Group, BSE, Ophthalmology, Contract, Inhalation, Pain management, PPL, Investment, Stock, McNeil Consumer Healthcare, NSE, Integrated services, PPS, CDMO, PEL, Board, CEO, OTC, Medication, Anesthetic, Financial services, Spasticity, PCC, Bombay Stock Exchange, Solution, Pharmaceutical industry, Fine chemical, Pharma

MUMBAI, Oct. 19, 2022 /PRNewswire/ --Piramal Pharma Limited (PPL) (Scrip Name: PPLPHARMA) today listed on the Indian stock exchanges, Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Key Points: 
  • MUMBAI, Oct. 19, 2022 /PRNewswire/ --Piramal Pharma Limited (PPL) (Scrip Name: PPLPHARMA) today listed on the Indian stock exchanges, Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).
  • In June 2020, PPL signed an agreement with The Carlyle Group Inc. to invest growth equity capital for a 20% stake in Piramal Pharma Limited.
  • Mr. Ajay Piramal, Chairman of Piramal Group, said, "Today, with the listing of Piramal Pharma Limited, we have ensured timely completion of the demerger process announced last year.
  • Ms. Nandini Piramal, Chairperson,PPL said, "We are pleased that Piramal Pharma is embarking on a new journey as a focused Pharma entity with a simplified corporate structure.

Piramal Pharma Limited lists on BSE and NSE

Retrieved on: 
Wednesday, October 19, 2022
Scrip, Allergan, National Stock Exchange, Growth, Piramal Group, The Carlyle Group, BSE, Ophthalmology, Contract, Inhalation, Pain management, PPL, Investment, Stock, McNeil Consumer Healthcare, NSE, Integrated services, PPS, CDMO, PEL, Board, CEO, OTC, Medication, Anesthetic, Financial services, Spasticity, PCC, Bombay Stock Exchange, Solution, Pharmaceutical industry, Fine chemical, Pharma

MUMBAI, Oct. 19, 2022 /PRNewswire/ --Piramal Pharma Limited (PPL) (Scrip Name: PPLPHARMA) today listed on the Indian stock exchanges, Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Key Points: 
  • MUMBAI, Oct. 19, 2022 /PRNewswire/ --Piramal Pharma Limited (PPL) (Scrip Name: PPLPHARMA) today listed on the Indian stock exchanges, Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).
  • In June 2020, PPL signed an agreement with The Carlyle Group Inc. to invest growth equity capital for a 20% stake in Piramal Pharma Limited.
  • Mr. Ajay Piramal, Chairman of Piramal Group, said, "Today, with the listing of Piramal Pharma Limited, we have ensured timely completion of the demerger process announced last year.
  • Ms. Nandini Piramal, Chairperson,PPL said, "We are pleased that Piramal Pharma is embarking on a new journey as a focused Pharma entity with a simplified corporate structure.

6-Month Data from the Surmodics SWING First-in-Human Study to be Presented at AMP Europe

Retrieved on: 
Friday, October 7, 2022
Biotechnology, Pharmaceutical, Surgery, General Health, Health, Medical Devices, Clinical Trials, Other Health, Quality of life, Disease, Risk, SEC, Sale, MS, Growth, Investor, PHD, Annual report, NASDAQ, Patient, Cell, Amputation, Restenosis, Technology, ONZM, Company, Auckland City Hospital, Safety, AMP, FRANZCR, Master of Medicine, Forward-looking statement, Aortoiliac occlusive disease, Pharmaceutical industry, FRACS, MBBS, Bachelor of Medicine, Bachelor of Surgery, Anesthetic

The session will be held on Tuesday, October 11, at the Amputation Prevention Symposium (AMP) in Lugano, Switzerland.

Key Points: 
  • The session will be held on Tuesday, October 11, at the Amputation Prevention Symposium (AMP) in Lugano, Switzerland.
  • He will review safety and efficacy data collected through 6-months of follow-up for 35 patients with occlusive disease of the infra-popliteal arteries who were treated at study sites in Australia, New Zealand, or locations in Europe.
  • Study subjects will be followed for 36 months after the index procedure.
  • I am excited to present the 6-month SWING data to an audience of my peers at AMP Europe.

Blue-Zone Technologies, Ltd. Secures $8 Million of Institutional Financing

Retrieved on: 
Tuesday, October 4, 2022
Mont Blanc, Anesthetic, Health Canada, GMP, Knowledge, Clermont-Ferrand, Sale, Lyon, Venture capital, Angers, CEO, Health, ACM, Hospital, Time, Physician, Loire-Atlantique, Targobank, LLC, Company, High-dependency unit, GLOBE, CIC, Caen, Technology, Paola Lattus, Industry, Regulation and licensure in engineering, Inhalation, Environment, Investment, Project assurance, National Society of Certified Healthcare Business Consultants, Pharmaceutical industry, Financial services, Blue Zone

In addition to the financial investment, we will leverage their extensive network and in-depth knowledge of the global healthcare sector.

Key Points: 
  • In addition to the financial investment, we will leverage their extensive network and in-depth knowledge of the global healthcare sector.
  • The next 12 months will be an exciting time for Blue-Zone as we scale-up our operation and accelerate our commercial efforts.
  • The companys mission is to reduce hospitals hazardous environmental waste and lower financial costs by applying Blue-Zones patented technology.
  • Round Pond Ventures, LLC is an investment arm of HPC Holdings, Inc (the holding company for the Halocarbon Family of Companies).

Innocoll and DURECT Announce U.S. launch of POSIMIR®

Retrieved on: 
Monday, September 26, 2022
Central nervous system, Injection, Safety, Bradycardia, Achievement, Patient, U.S. Securities and Exchange Commission, Bupivacaine, Technology, C-reactive protein, Pain management, Annual report, Headache, AH, Risk, Fatty liver disease, COVID-19, Respiratory arrest, Methemoglobinemia, Sale, Food, Diarrhea, Vomiting, Anesthetic, Bruise, Surgeon, DNA, Nausea, SEC, Patent, Dizziness, Allergy, Coma, FDA, NASH, Association, Shoulder joint, Tinnitus, Paresthesia, Form 10-K, Chondrolysis, United States patent law, Somnolence, SABER, Constipation, Marketing, Itch, Blood, Incidence, Hypersensitivity, Elective surgery, Private Securities Litigation Reform Act, Regulation of tobacco by the U.S. Food and Drug Administration, Chronic liver disease, CNS, Anemia, Dentistry, Pharmaceutical industry, Vaccine, Fever, Dysuria, Dysgeusia, Hypoesthesia

"We are excited to bring a potential cornerstone of multi-modal post-operative pain management to surgeons with the launch of POSIMIR," said Louis Pascarella, Chief Executive Officer of Innocoll.

Key Points: 
  • "We are excited to bring a potential cornerstone of multi-modal post-operative pain management to surgeons with the launch of POSIMIR," said Louis Pascarella, Chief Executive Officer of Innocoll.
  • Per the terms of the collaboration between Innocoll and DURECT, Innocoll will make a $2 million payment to DURECT triggered by the first commercial sale of POSIMIR.
  • Previously, in August 2022, DURECT was issued a new patent by the US Patent Office, extending US patent coverage of POSIMIR to at least 2041, resulting in an $8 million milestone payment by Innocoll to DURECT.
  • NOTE: POSIMIR is a trademark of Innocoll Pharmaceuticals Limited in the U.S. and a trademark of DURECT Corporation outside of the U.S. SABER is a trademark of DURECT Corporation.

Clinical Trial Finds that Virtual Reality Therapy May Serve as Effective Adjunct To Anesthesia For Surgical Procedures

Retrieved on: 
Wednesday, September 21, 2022
PLOS, Software, Anesthetic, Efficiency, BIRD Foundation, Beth Israel Deaconess Medical Center, FDA, MD, Anesthesia, Health, Nerve, Relaxation, Synthetic control method, Environment, Beth Israel, Hand, Patient satisfaction, Patient, Clinical trial, CEO, Technology, CE, Pain, Anxiety, Patient safety, Bariatric surgery, XR, Rancho Los Amigos National Rehabilitation Center, Extended reality, Pain management, Virtual reality, Rehabilitation, Hospital, VR, Dentistry, Metaverse

BOSTON, Sept. 21, 2022 /PRNewswire/ -- The results of a clinical trial using software from XRHealth, developer and operator of virtual treatment rooms in the metaverse, published in PLOS ONE demonstrated that virtual reality therapy may serve as an effective adjunct to anesthesia for surgical procedures. The trials were conducted with XRHealth's immersive virtual reality software.

Key Points: 
  • New Study Published in PLOS ONE Highlights Clinical Trial Findings; XRHealth Virtual Reality Therapy Aided Intraoperative Control of Pain and Anxiety without Intravenous Anesthetics
    BOSTON, Sept. 21, 2022 /PRNewswire/ --The results of a clinical trial using software from XRHealth , developer and operator of virtual treatment rooms in the metaverse, published in PLOS ONE demonstrated that virtual reality therapy may serve as an effective adjunct to anesthesia for surgical procedures.
  • Patients were randomized to intraoperative immersive virtual reality with intravenous anesthesia only given as needed, or to usual care as directed by the anesthesiologist.
  • The VR therapy software provided an immersive, engaging environment that guided patients through relaxation and pain reduction techniques while undergoing the surgery.
  • The company operates state-of-the-art therapeutic care Virtual Clinics, utilizing proprietary FDA and CE registered medical Extended Reality (XR) technology (virtual and augmented reality).